BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1107 related articles for article (PubMed ID: 27307795)

  • 21. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
    Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
    Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
    Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
    Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
    Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
    Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
    Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
    Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Silencing of
    Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological effects of hypomethylating agents.
    Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
    Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Straube J; Lane SW; Vu T
    Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of hypomethylating agents in the treatment of elderly patients with AML.
    Al-Ali HK; Jaekel N; Niederwieser D
    J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.